Incyte (INCY) Treasury Shares (2013 - 2024)

Incyte (INCY) reported Treasury Shares of $33.3 million for Q2 2024, up 49889.27% quarter-over-quarter from $66666.0 in Q2 2019.

Incyte (INCY) Treasury Shares (2013 - 2024) Analysis & Trends

Incyte has reported Treasury Shares for 8 years, with the latest figure at $33.3 million in Q2 2024.

For the quarter ending Q2 2024, Treasury Shares changed N/A year-over-year to $33.3 million; the trailing twelve-month figure through Jun 2024 stood at $33.3 million (changed N/A YoY), and the FY2018 full-year result was $545751.0, down 29.05% from the prior year.
Treasury Shares for Q2 2024 stood at $33.3 million, up from $66666.0 in the prior quarter.
The five-year high for Treasury Shares was $33.3 million in Q2 2024, with the low at $33.3 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	1.48 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	700,000.00
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Incyte	19.62 Bn	15.60 Bn	1.17 Bn	-

Download Data